Incepta Pharmaceuticals Ltd.

More than a year ago, New Zealand customs officials began intercepting several batches of injections marked with the brands Fitaro and Orsema, produced by the little-known Bangladeshi pharmaceutical company Incepta Pharmaceuticals. According to documents seen by Reuters, data provided by New Zealand's drug regulatory authority, Medsafe, showed that 14 injection pens seized at the border contained semaglutide, a patented substance that helps control blood sugar levels and appetite and is a key ingredient in Novo Nordisk's best-selling drugs Ozempic and Wegovy. Reuters found that against the backdrop of a surge in global demand for Ozempic, Incepta's drugs have become part of the Asian supply chain, producing and exporting cheap generic versions of Ozempic to countries around the world. Ozempic is developed for patients with type 2 diabetes, but its active ingredient semaglutide has also shown effectiveness in promoting weight loss. Novo Nordisk is targeting the anti-obesity drug Wegovy, with expectations that the market size for such weight loss drugs could reach $150 billion by the 2030s. According to Reuters, at least 106,000 packs of semaglutide drugs produced by Incepta in Asia have been shipped to 12 foreign markets, including the United States and the United Kingdom, which are countries protected by Ozempic patents. According to public records and information provided by a local regulatory official, Incepta did not respond to multiple requests for comment on Fitaro and Orsema. Both companies have been approved for sale in Bangladesh. The official from the Bangladesh Directorate General of Drug Administration said that Bangladeshi regulatory authorities have approved Incepta to export Fitaro or Orsema, but only if the company obtains approval from the receiving country. Due to not being authorized to speak to the media, the official declined to be named. Regulatory data shows that between August 2023 and May 2024, these injection pens, which were not authorized for use in New Zealand, were submitted to Medsafe and destroyed. Related video: WeightWatchers launches an Ozempic version despite FDA concerns (WCVB Boston) WeightWatchers announced that it will now offer a version of Ozempic to qualified members. Medsafe told Reuters that the destroyed batches of Fitaro and Orsema seemed to be intended for personal use, but did not comment on whether these drugs posed a health risk. "Drugs imported from overseas will not have been assessed and approved by Medsafe, and therefore pose a significant risk because the quality cannot be guaranteed to meet acceptable levels," the regulator added in response to Reuters' inquiries about the importation of semaglutide drugs. Reuters previously reported that semaglutide drugs from Bangladesh were being sold on the Indian online market IndiaMART. The latest report indicates that non-Novartis-produced semaglutide drugs are more widely distributed internationally. Reuters' investigation data comes from drug regulatory authorities in Australia, Brazil, New Zealand, and the United States; information from commercial customs data providers in Kenya, Uzbekistan, Venezuela, Hong Kong, and the United Arab Emirates; and drug seizure records from the United Kingdom, Switzerland, and Ireland. In addition, interviews with exhibitors at a trade exhibition, reviews of commercial customs data providers, and data from the Brazilian Ministry of Justice show that at least six little-known companies (four of which are based in Asia) produce semaglutide-based drugs and ship their products overseas. According to commercial customs data providers, an interview with an employee of Nanjing Hanxin Pharmaceutical Technology Co., Ltd. in China, and a review of a website and social media application by Reuters, at least three of these companies import key ingredients from China, and at least one product is promoted online and in person outside the country of origin. Reuters' reporting indicates that these companies have taken advantage of global patent exemptions allowed in less developed countries and lax patent enforcement in countries such as China. Novo Nordisk told Reuters that as the only approved producer of semaglutide globally, the company cannot ensure the safety or effectiveness of products声称 to contain semaglutide from other manufacturers. Although Novo Nordisk's semaglutide products are protected by international licenses, the least developed countries listed by the United Nations, such as Bangladesh and Laos, enjoy exemptions from industry patent rules. This Danish company has rapidly risen to become one of Europe's most valuable companies, with a market value of about $400 billion. The company stated on its official website that it does not enforce patent protection in developing countries. Given the strong market demand for Ozempic, potential patent infringement currently seems to have a limited financial impact on Novo Nordisk. Nicholas Anderson, portfolio manager and managing director at Thornburg Investment Management, an asset management company, pointed out: "Currently, illegal drugs do not pose a threat to Novo Nordisk's sales because they are selling every dose they can produce." The company holds shares in Novo Nordisk. However, this practice of generics has raised concerns in the healthcare sector. According to records from drug regulatory authorities and responses to Reuters' inquiries, drug regulatory authorities in at least six countries, including the United States, the United Kingdom, and Ireland, have refused, destroyed, or seized some of Incepta's semaglutide drugs. In one case, according to an announcement by a local drug regulatory authority in January, unauthorized semaglutide was recalled in South Africa in December due to potential health risks. The authority told Reuters that the ingredient came from a Chinese supplier not authorized to produce Ozempic ingredients, but did not provide further details. The announcement stated: "The semaglutide found in these unapproved substances may contain unexpected impurities or degradation products, which may have unknown effects on patients." Reuters found no evidence that these products have harmed patients, but their circulation could exacerbate public health concerns about the medical industry.

Over the past seven days, the pharmaceutical sector has experienced significant volatility. Workers in the sector have launched protests, demanding regularization of work, wage increases, more holidays and other related issues. The workers' actions have led to the temporary shutdown of 27 major drug manufacturers. While making their demands, protesters carried out acts of vandalism inside factories, holding officials of industrial units hostage and forcing them to sign documents that met their demands. The factory owners claimed that outsiders were inciting unrest in their factories. While some factories resumed operations after meeting initial demands, officials and owners reported new protests and more demands. They also noted that outside actors, in addition to workers, were involved in the protests at several factories. Over the past week, workers have staged protests in several parts of the country, including Savar, Ghazipur and Maimensingh. The Bangladesh Pharmaceutical Industry Association reported that at least 27 companies had their factories shut down, including Square, Acme, Orion, Beximco and Incepta. Abdul Muktadir, president of the Bangladesh Pharmaceutical Industry Association, told TBS: "We are willing to meet with the workers to address their legitimate claims. However, holding an official hostage and then making unreasonable demands is unacceptable." He stressed that the protests must be resolved quickly with government intervention, otherwise the country's pharmaceutical industry will face a crisis, which he expressed concern about. Muktadir also said: "The hostage-taking and vandalism are unjust. The day after meeting one demand, the workers made a new one. It appears to be a conspiracy to destroy the pharmaceutical industry. If the protests continue in this way, these companies will have to choose to shut down." Entrepreneurs say the market is currently being kept supplied by existing inventories. However, if the impasse continues, it could create a major crisis in the country's drug supply, disrupting medical services and affecting exports. They called on the government to support the immediate resumption of production at all factories. On Wednesday, workers at the UnitedHealth Pharmaceutical Company factory in Rajendrapur, Gazipur, went on strike. The workers made 20 demands, including the elimination of wage differentials. They are mainly demanding a ballot to form a union, a daily minimum wage of 750 TECk for temporary workers, and a guarantee that all workers are converted into regular employees within six months of starting their jobs. They also demanded an increase in the minimum wage from 8,500 TECk to 20,500 TECk and a minimum night allowance of 500 TECk. Other demands include a 20 percent increase in annual salary, a two-day holiday system, attendance bonuses and year-end production bonuses, and automatic promotion after three years. Workers also restricted the movement of top management during the strike. "What we are protesting is discrimination, what we are after is equal opportunity for everyone," factory foreman Mohammed Hannan told TBS. A UnitedHealth official, who spoke on condition of anonymity, noted that while critical work at the plant is carried out by chemists and permanent employees, some temporary workers and aides have been protesting at the plant for days with outside support. He added that while the employers initially accepted some of their demands, the protesters then made new demands. While communicating with the instigators, a number of outsiders were found, but none were willing to be identified. Despite the presence of law enforcement officers, the protesters did not comply with police instructions. Three days after the plant was shut down, Acme Lab, one of the country's leading drug manufacturers, was able to resume operations thanks to the intervention of army personnel and an agreement with workers. An Acme official explained that temporary workers such as foremen, mechanics, security guards, cafeteria workers, etc. had initially asked for the minimum wage to be doubled. Employers agreed to raise wages by 50 percent to 12,000 baht. The next day, however, with outside support, workers began demanding that the minimum wage be nearly tripled to 20,500 baht and made other demands that were difficult to meet. The country's major pharmaceutical companies, Square and Incepta, have suspended operations at their production facilities for several days due to labor protests. Mr. Abdul Muktadir, Managing Director of Incepta Pharmaceuticals, said that while the pharmaceutical industry association has been working hand in hand with workers to advance the industry for the past half century, it is not clear why workers continue to make new demands and protest. Speaking at a press conference on Tuesday evening, Mr Muktadir said: "Scientists and managers are being held hostage and workers are claiming that they will not release the detained officials unless they sign the documents they are demanding." He further revealed that "about 400 Incepta employees were quarantined from 7am on Tuesday until 3am the following morning." The protesters include many people we don't know, and they are making demands that are almost impossible to achieve." At a factory in Gazipur, workers detained all officials from Monday morning until Tuesday afternoon to pursue their demands. More than 200 managers at the plant were detained by protesters for two days. An official at the factory said in a Facebook post that at least 40 of them were women, some of them pregnant. The plant's general manager told TBS that "the food in the canteen has run out and there is not enough space inside the factory for so many officials to stay overnight, resulting in a difficult night for everyone." The army then stepped in and it took intense negotiations to quell the workers' discontent." Production at Orion Pharmaceuticals was also disrupted by the protests. Zareen Karim, managing director of Orion Pharmaceuticals, said: "We have never had a situation where a manager has been held hostage and forced to accept a request." "We want to address workers' concerns and seek a reasonable solution to meet their demands regarding wage increases." If this issue is not resolved in time, it will have a negative impact on exports." Zareen mentioned that the minimum wage is currently 8,500 baht, and they want it to increase at a reasonable rate. "The government should promote dialogue between owners and workers. The regularization of workers should be negotiated with the government because sudden changes are difficult to adapt to." Meanwhile, the advisory committee met on Wednesday to address labor unrest and protests in the ready-to-wear apparel industry and several other sectors. Instructions for joint police and military operations were issued at the meeting, aimed at curbing foreign intervention and encouraging workers to resume work. At present, there is no consultation with business owners on wages in the pharmaceutical sector. The Secretary of the Ministry of Labour and Employment (day-to-day affairs), Dr Jahangir Hossain, revealed that a wage committee has been set up to review and raise the minimum wage for workers in the pharmaceutical industry. "A resolution was taken at the first meeting, but the second meeting, originally scheduled for July last year, had to be postponed due to the political situation. We plan to meet with the owners of the pharmaceutical industry soon." Bangladesh is almost self-sufficient in the medical sector, with about 98% of the country's medical needs being met. According to data from the Drug Administration, Bangladesh currently has 295 pharmaceutical manufacturing enterprises. The country's pharmaceutical market is worth 3 trillion baht a year. In addition, medicines produced in Bangladesh have been exported to 157 countries with an annual export value of approximately US $200 million.

NEW YORK, Jan. 9, 2023 /PRNewswire/ -- Antibiotics market insights - Continue Reading Technavio has announced its latest market research report titled Global Antibiotics Market 2023-2027 Vendors: 15+, Including Abbott Laboratories, AbbVie Inc., Armata Pharmaceuticals Inc., Aspen Pharmacare Holdings Ltd, Astellas Pharma Inc., Aurobindo Pharma Ltd., Bayer AG, F. Hoffmann La Roche Ltd., Flynn Pharma Ltd., GlaxoSmithKline Plc, Incepta Pharmaceuticals Ltd., Johnson and Johnson, Lupin Ltd., Mayne Pharma Group Ltd., Melinta Therapeutics LLC, Merck KGaA, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd. among others Coverage: Parent market analysis; key drivers, major trends, and challenges; customer and vendor landscape; vendor product insights and recent developments; key vendors; and market positioning of vendors Segments: Product (broad-spectrum antibiotics and narrow-spectrum antibiotics), route of administration (intravenous, oral, and others), and geography (Asia, North America, Europe, and Rest of World). To understand more about the antibiotics market, request a sample report The antibiotics market report provides critical information and factual data, with a qualitative and quantitative study of the market based on market drivers and limitations as well as future prospects. Why Buy? Add credibility to strategy Analyzes competitor's offerings Get a holistic view of the market Grow your profit margin with Technavio- Buy the Report In 2017, the antibiotics market was valued at USD 40,633.93 million. From a regional perspective, Asia held the largest market share, valued at USD 14,893.29 million. The antibiotics market size is estimated to grow by USD 17,066.66 million from 2022 to 2027 at a CAGR of 6.07% according to Technavio. Antibiotics market - Customer landscape To help companies evaluate and develop growth strategies, the report outlines – Key purchase criteria Adoption rates Adoption lifecycle Drivers of price sensitivity For highlights on customer landscape analysis, download a sample! Global antibiotics market - Vendor insights The growing competition in the market is compelling vendors to adopt various growth strategies such as promotional activities and spending on advertisements to improve the visibility of their services. Technavio report analyzes the market's competitive landscape and offers information on several market vendors including - AbbVie Inc: The company offers HUMIRA antibiotics drug which is designed to reduce pain and swelling. Astellas Pharma Inc: The company offers XTANDI which is designed as a prescription medicine to treat men with prostate cancer issues. Aspen Pharmacare Holdings Ltd: The company offers Aggrastat antibiotic medicine which is designed to treat the symptoms of blood clots and heart attack issues. Global antibiotics market – Market dynamics Major drivers- Rising prevalence of infectious diseases Growing awareness of various diseases and their treatment Special regulatory designations KEY challenges – Development of antibiotic-resistant strains Entry of generics The limited interest of pharmaceutical companies in investing in antibiotic research activities Drivers, & Challenges have an impact on market dynamics and can impact businesses. Find some insights from a sample report! What are the key data covered in this antibiotics market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the antibiotics market between 2023 and 2027 Precise estimation of the size of the antibiotics market and its contribution to the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of the antibiotics market across Asia, North America, Europe, and Rest of World (ROW) A thorough analysis of the market's competitive landscape and detailed information about vendors Comprehensive analysis of factors that will challenge the growth of antibiotics market vendors Gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform Related Reports: Anti-inflammatory Therapeutics Market by Application, Drug Class, and Geography - Forecast and Analysis 2023-2027: The anti-inflammatory therapeutics market is estimated to grow at a CAGR of 6.7% between 2022 and 2027. The size of the market is forecast to increase by USD 39.32 billion. The unmet need for safer biologics for RA is notably driving the market growth, although factors such as the loss of patents may impede market growth. Anti-obesity Drugs Market by Type, Drug Class, and Geography - Forecast and Analysis 2023-2027: The anti-obesity drugs market is estimated to grow at a CAGR of 12.5% between 2022 and 2027. The size of the market is forecast to increase by USD 13,693.43 million. The growing obese population is notably driving the market growth, although factors such as limited reimbursement for anti-obesity drugs may impede the market growth. Browse for Technavio "Health Care" Research Reports Table of Contents 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Product Exhibit 06: Executive Summary – Chart on Market Segmentation by Route of Administration Exhibit 07: Executive Summary – Chart on Incremental Growth Exhibit 08: Executive Summary – Data Table on Incremental Growth Exhibit 09: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 10: Parent market Exhibit 11: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 12: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 13: Market segments 3.3 Market size 2022 3.4 Market outlook: Forecast for 2022-2027 Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million) Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million) Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) 4 Historic Market Size 4.1 Global antibiotics market 2022 - 2027 Exhibit 18: Historic Market Size – Data Table on Global antibiotics market 2022 - 2027 ($ million) 4.2 Product Segment Analysis 2022 - 2027 Exhibit 19: Historic Market Size – Product Segment 2022 - 2027 ($ million) 4.3 Route of administration Segment Analysis 2022 - 2027 Exhibit 20: Historic Market Size – Route of administration Segment 2022 - 2027 ($ million) 4.4 Geography Segment Analysis 2022 - 2027 Exhibit 21: Historic Market Size – Geography Segment 2022 - 2027 ($ million) 4.5 Country Segment Analysis 2022 - 2027 Exhibit 22: Historic Market Size – Country Segment 2022 - 2027 ($ million) 5 Five Forces Analysis 5.1 Five forces summary Exhibit 23: Five forces analysis - Comparison between 2022 and 2027 5.2 Bargaining power of buyers Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027 5.3 Bargaining power of suppliers Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027 5.4 Threat of new entrants Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027 5.5 Threat of substitutes Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027 5.6 Threat of rivalry Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027 5.7 Market condition Exhibit 29: Chart on Market condition - Five forces 2022 and 2027 6 Market Segmentation by Product 6.1 Market segments Exhibit 30: Chart on Product - Market share 2022-2027 (%) Exhibit 31: Data Table on Product - Market share 2022-2027 (%) 6.2 Comparison by Product Exhibit 32: Chart on Comparison by Product Exhibit 33: Data Table on Comparison by Product 6.3 Broad-spectrum antibiotics - Market size and forecast 2022-2027 Exhibit 34: Chart on Broad-spectrum antibiotics - Market size and forecast 2022-2027 ($ million) Exhibit 35: Data Table on Broad-spectrum antibiotics - Market size and forecast 2022-2027 ($ million) Exhibit 36: Chart on Broad-spectrum antibiotics - Year-over-year growth 2022-2027 (%) Exhibit 37: Data Table on Broad-spectrum antibiotics - Year-over-year growth 2022-2027 (%) 6.4 Narrow-spectrum antibiotics - Market size and forecast 2022-2027 Exhibit 38: Chart on Narrow-spectrum antibiotics - Market size and forecast 2022-2027 ($ million) Exhibit 39: Data Table on Narrow-spectrum antibiotics - Market size and forecast 2022-2027 ($ million) Exhibit 40: Chart on Narrow-spectrum antibiotics - Year-over-year growth 2022-2027 (%) Exhibit 41: Data Table on Narrow-spectrum antibiotics - Year-over-year growth 2022-2027 (%) 6.5 Market opportunity by Product Exhibit 42: Market opportunity by Product ($ million) 7 Market Segmentation by Route of Administration 7.1 Market segments Exhibit 43: Chart on Route of Administration - Market share 2022-2027 (%) Exhibit 44: Data Table on Route of Administration - Market share 2022-2027 (%) 7.2 Comparison by Route of Administration Exhibit 45: Chart on Comparison by Route of Administration Exhibit 46: Data Table on Comparison by Route of Administration 7.3 Intravenous - Market size and forecast 2022-2027 Exhibit 47: Chart on Intravenous - Market size and forecast 2022-2027 ($ million) Exhibit 48: Data Table on Intravenous - Market size and forecast 2022-2027 ($ million) Exhibit 49: Chart on Intravenous - Year-over-year growth 2022-2027 (%) Exhibit 50: Data Table on Intravenous - Year-over-year growth 2022-2027 (%) 7.4 Oral - Market size and forecast 2022-2027 Exhibit 51: Chart on Oral - Market size and forecast 2022-2027 ($ million) Exhibit 52: Data Table on Oral - Market size and forecast 2022-2027 ($ million) Exhibit 53: Chart on Oral - Year-over-year growth 2022-2027 (%) Exhibit 54: Data Table on Oral - Year-over-year growth 2022-2027 (%) 7.5 Others - Market size and forecast 2022-2027 Exhibit 55: Chart on Others - Market size and forecast 2022-2027 ($ million) Exhibit 56: Data Table on Others - Market size and forecast 2022-2027 ($ million) Exhibit 57: Chart on Others - Year-over-year growth 2022-2027 (%) Exhibit 58: Data Table on Others - Year-over-year growth 2022-2027 (%) 7.6 Market opportunity by Route of Administration Exhibit 59: Market opportunity by Route of Administration ($ million) 8 Customer Landscape 8.1 Customer landscape overview Exhibit 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 9 Geographic Landscape 9.1 Geographic segmentation Exhibit 61: Chart on Market share by geography 2022-2027 (%) Exhibit 62: Data Table on Market share by geography 2022-2027 (%) 9.2 Geographic comparison Exhibit 63: Chart on Geographic comparison Exhibit 64: Data Table on Geographic comparison 9.3 Asia - Market size and forecast 2022-2027 Exhibit 65: Chart on Asia - Market size and forecast 2022-2027 ($ million) Exhibit 66: Data Table on Asia - Market size and forecast 2022-2027 ($ million) Exhibit 67: Chart on Asia - Year-over-year growth 2022-2027 (%) Exhibit 68: Data Table on Asia - Year-over-year growth 2022-2027 (%) 9.4 North America - Market size and forecast 2022-2027 Exhibit 69: Chart on North America - Market size and forecast 2022-2027 ($ million) Exhibit 70: Data Table on North America - Market size and forecast 2022-2027 ($ million) Exhibit 71: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibit 72: Data Table on North America - Year-over-year growth 2022-2027 (%) 9.5 Europe - Market size and forecast 2022-2027 Exhibit 73: Chart on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 74: Data Table on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 75: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibit 76: Data Table on Europe - Year-over-year growth 2022-2027 (%) 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 Exhibit 77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibit 78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibit 79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibit 80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) 9.7 US - Market size and forecast 2022-2027 Exhibit 81: Chart on US - Market size and forecast 2022-2027 ($ million) Exhibit 82: Data Table on US - Market size and forecast 2022-2027 ($ million) Exhibit 83: Chart on US - Year-over-year growth 2022-2027 (%) Exhibit 84: Data Table on US - Year-over-year growth 2022-2027 (%) 9.8 China - Market size and forecast 2022-2027 Exhibit 85: Chart on China - Market size and forecast 2022-2027 ($ million) Exhibit 86: Data Table on China - Market size and forecast 2022-2027 ($ million) Exhibit 87: Chart on China - Year-over-year growth 2022-2027 (%) Exhibit 88: Data Table on China - Year-over-year growth 2022-2027 (%) 9.9 India - Market size and forecast 2022-2027 Exhibit 89: Chart on India - Market size and forecast 2022-2027 ($ million) Exhibit 90: Data Table on India - Market size and forecast 2022-2027 ($ million) Exhibit 91: Chart on India - Year-over-year growth 2022-2027 (%) Exhibit 92: Data Table on India - Year-over-year growth 2022-2027 (%) 9.10 UK - Market size and forecast 2022-2027 Exhibit 93: Chart on UK - Market size and forecast 2022-2027 ($ million) Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 ($ million) Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%) Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%) 9.11 Japan - Market size and forecast 2022-2027 Exhibit 97: Chart on Japan - Market size and forecast 2022-2027 ($ million) Exhibit 98: Data Table on Japan - Market size and forecast 2022-2027 ($ million) Exhibit 99: Chart on Japan - Year-over-year growth 2022-2027 (%) Exhibit 100: Data Table on Japan - Year-over-year growth 2022-2027 (%) 9.12 Market opportunity by geography Exhibit 101: Market opportunity by geography ($ million) 10 Drivers, Challenges, and Trends 10.1 Market drivers 10.2 Market challenges 10.3 Impact of drivers and challenges Exhibit 102: Impact of drivers and challenges in 2022 and 2027 10.4 Market trends 11 Vendor Landscape 11.1 Overview 11.2 Vendor landscape Exhibit 103: Overview on Criticality of inputs and Factors of differentiation 11.3 Landscape disruption Exhibit 104: Overview on factors of disruption 11.4 Industry risks Exhibit 105: Impact of key risks on business 12 Vendor Analysis 12.1 Vendors covered Exhibit 106: Vendors covered 12.2 Market positioning of vendors Exhibit 107: Matrix on vendor position and classification 12.3 Abbott Laboratories Exhibit 108: Abbott Laboratories - Overview Exhibit 109: Abbott Laboratories - Business segments Exhibit 110: Abbott Laboratories - Key news Exhibit 111: Abbott Laboratories - Key offerings Exhibit 112: Abbott Laboratories - Segment focus 12.4 AbbVie Inc. Exhibit 113: AbbVie Inc. - Overview Exhibit 114: AbbVie Inc. - Product / Service Exhibit 115: AbbVie Inc. - Key news Exhibit 116: AbbVie Inc. - Key offerings 12.5 Aspen Pharmacare Holdings Ltd Exhibit 117: Aspen Pharmacare Holdings Ltd - Overview Exhibit 118: Aspen Pharmacare Holdings Ltd - Business segments Exhibit 119: Aspen Pharmacare Holdings Ltd - Key offerings Exhibit 120: Aspen Pharmacare Holdings Ltd - Segment focus 12.6 Astellas Pharma Inc. Exhibit 121: Astellas Pharma Inc. - Overview Exhibit 122: Astellas Pharma Inc. - Product / Service Exhibit 123: Astellas Pharma Inc. - Key offerings 12.7 Aurobindo Pharma Ltd. Exhibit 124: Aurobindo Pharma Ltd. - Overview Exhibit 125: Aurobindo Pharma Ltd. - Product / Service Exhibit 126: Aurobindo Pharma Ltd. - Key offerings 12.8 Bayer AG Exhibit 127: Bayer AG - Overview Exhibit 128: Bayer AG - Business segments Exhibit 129: Bayer AG - Key offerings Exhibit 130: Bayer AG - Segment focus 12.9 F. Hoffmann La Roche Ltd. Exhibit 131: F. Hoffmann La Roche Ltd. - Overview Exhibit 132: F. Hoffmann La Roche Ltd. - Business segments Exhibit 133: F. Hoffmann La Roche Ltd. - Key news Exhibit 134: F. Hoffmann La Roche Ltd. - Key offerings Exhibit 135: F. Hoffmann La Roche Ltd. - Segment focus 12.10 GlaxoSmithKline Plc Exhibit 136: GlaxoSmithKline Plc - Overview Exhibit 137: GlaxoSmithKline Plc - Business segments Exhibit 138: GlaxoSmithKline Plc - Key offerings Exhibit 139: GlaxoSmithKline Plc - Segment focus 12.11 Incepta Pharmaceuticals Ltd. Exhibit 140: Incepta Pharmaceuticals Ltd. - Overview Exhibit 141: Incepta Pharmaceuticals Ltd. - Product / Service Exhibit 142: Incepta Pharmaceuticals Ltd. - Key offerings 12.12 Johnson and Johnson Exhibit 143: Johnson and Johnson - Overview Exhibit 144: Johnson and Johnson - Business segments Exhibit 145: Johnson and Johnson - Key news Exhibit 146: Johnson and Johnson - Key offerings Exhibit 147: Johnson and Johnson - Segment focus 12.13 Lupin Ltd. Exhibit 148: Lupin Ltd. - Overview Exhibit 149: Lupin Ltd. - Product / Service Exhibit 150: Lupin Ltd. - Key news Exhibit 151: Lupin Ltd. - Key offerings 12.14 Mayne Pharma Group Ltd. Exhibit 152: Mayne Pharma Group Ltd. - Overview Exhibit 153: Mayne Pharma Group Ltd. - Business segments Exhibit 154: Mayne Pharma Group Ltd. - Key offerings Exhibit 155: Mayne Pharma Group Ltd. - Segment focus 12.15 Merck KGaA Exhibit 156: Merck KGaA - Overview Exhibit 157: Merck KGaA - Business segments Exhibit 158: Merck KGaA - Key news Exhibit 159: Merck KGaA - Key offerings Exhibit 160: Merck KGaA - Segment focus 12.16 Pfizer Inc. Exhibit 161: Pfizer Inc. - Overview Exhibit 162: Pfizer Inc. - Product / Service Exhibit 163: Pfizer Inc. - Key news Exhibit 164: Pfizer Inc. - Key offerings 12.17 Sanofi SA Exhibit 165: Sanofi SA - Overview Exhibit 166: Sanofi SA - Business segments Exhibit 167: Sanofi SA - Key news Exhibit 168: Sanofi SA - Key offerings Exhibit 169: Sanofi SA - Segment focus 13 Appendix 13.1 Scope of the report 13.2 Inclusions and exclusions checklist Exhibit 170: Inclusions checklist Exhibit 171: Exclusions checklist 13.3 Currency conversion rates for US$ Exhibit 172: Currency conversion rates for US$ 13.4 Research methodology Exhibit 173: Research methodology Exhibit 174: Validation techniques employed for market sizing Exhibit 175: Information sources 13.5 List of abbreviations Exhibit 176: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio